• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    President, CEO Shelton Jerrell was granted 30,000 shares and sold $29,068 worth of shares (4,620 units at $6.29), increasing direct ownership by 3% to 765,399 units (SEC Form 4)

    3/18/25 7:05:37 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    SHELTON JERRELL

    (Last) (First) (Middle)
    C/O CRYOPORT INC.
    112 WESTWOOD PLACE, SUITE 350

    (Street)
    BRENTWOOD TN 37027

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Cryoport, Inc. [ CYRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President, CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/14/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock(1) 03/14/2025 A 30,000 A $0(1) 770,019 D
    Common Stock 03/17/2025 S(2) 4,620 D $6.2917 765,399 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $7.05 03/14/2025 A 75,000 (3) 03/14/2032 Common Stock 75,000 $0 75,000 D
    Explanation of Responses:
    1. Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2026.
    2. Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
    3. 1/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2025.
    /s/ Jerrell Shelton 03/18/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CYRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYRX

    DatePrice TargetRatingAnalyst
    3/24/2025$10.00Neutral → Buy
    UBS
    12/19/2024$11.00Buy
    Guggenheim
    12/19/2024$11.00Buy
    Canaccord Genuity
    8/7/2024$20.00 → $8.00Buy → Hold
    Jefferies
    7/31/2024$19.00 → $15.00Neutral → Buy
    B. Riley Securities
    5/3/2024$22.00 → $19.00Buy → Neutral
    B. Riley Securities
    4/4/2024$17.00 → $21.00Buy
    Jefferies
    3/13/2024$19.00 → $18.00Buy
    Needham
    More analyst ratings

    $CYRX
    Financials

    Live finance-specific insights

    See more
    • Cryoport Reports First Quarter 2025 Financial Results

      Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over yearQ1 2025 revenue from continuing operations of $41.0 million, up 10% year over yearSupporting 711 global clinical trials as of March 31, 2025Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025.  Jerrell Shelton, C

      5/7/25 4:05:00 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025

      NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Wednesday,

      4/24/25 8:30:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"

      DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.BONN, Germany and NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- DHL Group ("DHL"), the world's leading logistics provider, and Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport"), a global provider of supply chain solutions for the

      3/31/25 9:06:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cryoport upgraded by UBS with a new price target

      UBS upgraded Cryoport from Neutral to Buy and set a new price target of $10.00

      3/24/25 8:25:01 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Cryoport with a new price target

      Guggenheim initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00

      12/19/24 7:35:39 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Cryoport with a new price target

      Canaccord Genuity initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00

      12/19/24 7:35:29 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    SEC Filings

    See more
    • SEC Form SD filed by CryoPort Inc.

      SD - Cryoport, Inc. (0001124524) (Filer)

      5/30/25 4:31:07 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.

      SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)

      5/15/25 7:41:28 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.

      SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)

      5/15/25 12:34:32 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hariri Robert J sold $76,250 worth of shares (12,500 units at $6.10), decreasing direct ownership by 61% to 8,061 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      5/30/25 7:00:17 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Sawicki Mark W sold $9,364 worth of shares (1,349 units at $6.94), decreasing direct ownership by 2% to 84,087 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      3/26/25 7:01:07 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Stefanovich Robert sold $7,428 worth of shares (1,070 units at $6.94), decreasing direct ownership by 0.56% to 190,349 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      3/26/25 7:00:42 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Moffitt Cancer Center and Cryoport Announce Strategic Collaboration

      Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ:CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that i

      1/14/25 8:30:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cryoport Announces Appointment of Linda Baddour to its Board of Directors

      NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She

      3/3/21 4:08:00 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Appoints Martin Schmieg to Board of Directors

      BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L

      12/1/20 6:30:00 AM ET
      $BCTX
      $CLBS
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Managed Health Care

    $CYRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cryoport Reports First Quarter 2025 Financial Results

      Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over yearQ1 2025 revenue from continuing operations of $41.0 million, up 10% year over yearSupporting 711 global clinical trials as of March 31, 2025Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025.  Jerrell Shelton, C

      5/7/25 4:05:00 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025

      NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Wednesday,

      4/24/25 8:30:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"

      DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.BONN, Germany and NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- DHL Group ("DHL"), the world's leading logistics provider, and Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport"), a global provider of supply chain solutions for the

      3/31/25 9:06:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CryoPort Inc.

      SC 13G - Cryoport, Inc. (0001124524) (Subject)

      11/14/24 4:02:52 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

      SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

      11/14/24 1:34:13 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

      SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

      11/13/24 7:16:51 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care